Skip to content

Released Nov 9, 2026, before the open

10-Q filed Nov 9, 2026, 40 days after period end · 0001171843-26-007258

Q3 2026 · 10-Q
Revenue—
Net Income-$27.17MN/M vs Q3 2025N/M vs Q2 2026
EPS, diluted—
Operating Income-$28,800,000N/M
Operating Cash Flowderived-$16,317,000N/M
Free Cash Flowderived-$16,423,000N/M

What the release said

On November 9, 2026, Compass Therapeutics, Inc. issued a press release announcing financial results for the quarter and nine months ended September 30, 2026.

Compass reported a net loss of $27.2 million, or $0.15 per common share, for the quarter ended September 30, 2026, compared with $14.3 million, or $0.08 per share, for the same period in 2025.2

Research and development expenses were $22.0 million for the quarter, up from $12.8 million, primarily driven by $8.6 million of manufacturing costs related to tovecimig.3

General and administrative expenses were $6.8 million for the quarter, compared with $3.0 million a year earlier, including $1.5 million of pre-commercialization expenses.4

Cash and marketable securities were $163 million as of September 30, 2026, which the company expects will fund operations into 2028.56

In September 2026, the FDA recommended an additional study demonstrating a survival benefit before a BLA submission, and Compass does not believe a new trial is warranted before submitting a BLA.7

Net loss, three months ended September 30, 2026
$27.2 million Compared with $14.3 million for the same period in 20252
Net loss per share, three months ended September 30, 2026
$0.15 Compared with $0.08 per common share for the same period in 20252
Net loss, nine months ended September 30, 2026
$70.6 million Compared with $50.8 million for the same period in 20252
R&D expenses, three months ended September 30, 2026
$22.0 million Compared with $12.8 million for the same period in 2025, an increase of $9.2 million or 72%3
G&A expenses, three months ended September 30, 2026
$6.8 million Compared with $3.0 million for the same period in 2025, an increase of $3.8 million or 126%4
Cash and marketable securities, September 30, 2026
$163 million Compared with $209 million as of December 31, 20256
Thaler Agent · checked against the filing
Open the reading ›
The release

Same quarter

MetricQ3 2026Q3 2025Q3 2024Q3 2023
Revenue—$0.00$0.00$0.00
Net Income-$27.17M-$14.26M-$10.48M-$9.96M

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Compass Therapeutics, Inc. · CIK 1738021 · Engraved from SEC EDGAR